April 8, 2013

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.

The following patent record is from the CAplusSM database.

CAPLUS COPYRIGHT 2013 ACS

Patent Number: WO 2013003298
Title: Preparation of substituted 2-(imidazo[1,2-a]pyridin-7-yl)-[1,2,4]triazolo[1,5-a]pyrazines as inhibitors of PDE10
Inventor(s): Schmitz, William D.; Debenedetto, Mikkel V.; Kimura, S. Roy
Patent Assignee(s): Bristol-Myers Squibb Company, USA
Source: PCT Int. Appl., 59pp. CODEN: PIXXD2
Language: English

Abstract:
The title compds. I [R = cycloalkyl or II (wherein Q = N or CR1; Q1 = N or CR4; R1-R5 = H, alkoxy, alkyl, etc.); R6 = H, alkyl; X = N, CR7; one of R7 and R8 = H, CN, halo, etc., and the other = (un)substituted III containing 2-4 N atoms (Y = N or CH; Z = N or C); with the proviso], useful as PDE10 inhibitors, were prepared and claimed. E.g., a multi-step synthesis of IV, starting from Me 2-aminoisonicotinate, was described. Exemplified compds. I were tested in the PDE10a inhibition assay (data given for representative compds. I). Compns. comprising compds. I and methods for using the compds. I to inhibit PDE10 are also disclosed.

Please note:  Abstracts and Titles for patent records in CAplus are routinely enhanced to better describe the claimed invention. The title of the PCT publication is Inhibitors of PDE10.

 View the full-text here.

Recent News


    June 29, 2015 | CAS Assigns the 100 Millionth CAS
    Registry Number to a Substance Designed to
    Treat Acute Myeloid Leukemia
   
    March 17, 2015 | New Content Provides Regulatory
    Professionals with Additional Value

    February 9, 2015 | Major New STN Release Delivers
    Essential Biomedical and Patent Content to IP
    Professionals

                                                                       More News >> 
 
 

Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624
 Email: cas-pr@cas.org